Midway

Midway Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapies that protect and restore the integrity of the mucosal barrier. The company's lead programs utilize high molecular weight polymers to prevent bacterial translocation and the systemic inflammatory response associated with various gastrointestinal and systemic diseases. Their primary focus includes treating conditions such as graft-versus-host disease, inflammatory bowel disease, and radiation-induced injury. By stabilizing the gut's protective lining, Midway aims to provide a novel approach to managing complex inflammatory and infectious conditions. The company's technology is based on research from the University of Chicago and offers a non-antibiotic method to prevent pathogen-host interactions.